Aller au contenu principal
Accès ouvert déclaré 2026 article

Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015–2023

1Citations signalées — pas une note de qualité
5Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

ABSTRACT Chronic liver diseases cause a significant burden in Asia. This study aims to characterise the pattern and factors associated with advanced chronic liver disease (aCLD) in a large cohort from Mongolia, which has the highest rate of liver cancer globally. This is a cross‐sectional analysis of HBsAg tested adults (≥ 18 years) with available liver stiffness measurement (LSM) and/or platelet count at initial visit at a hepatology centre, Ulaanbaatar, Mongolia during 2015–2023. Definition of aCLD was LSM ≥ 12.5 kPa or platelet count < 150*10 9 cells/L. The annual percentage change (APC) of the incidence rates and factors associated with aCLD were assessed via logistic regression models. Out of 17,711 persons identified, 2517 (14.2%) had aCLD at initial visit, with a mean age (±SD) of 50.1 (12.0) years, 23.6% below 40 years old and 53.2% were female. The prevalence of HBsAg+, anti‐HDV+, HDV RNA+, and anti‐HCV+ was 61.6%, 78.6%, 64.6% and 57.9% in aCLD, respectively. Among aCLD, three‐fourths had an intermediate to high 5‐year risk of hepatocellular carcinoma (HCC) with 25.0%, and 17.1% having previously received anti‐HBV and anti‐HCV therapies, respectively. The overall rate of aCLD declined (APC −7.8%), mainly due to decline in anti‐HCV+ cases (APC −15.0%), while it significantly increased for anti‐HDV+ over study period (APC 3.3%). In a large cohort of attendees at a hepatology centre in Mongolia, the prevalence of aCLD declined associated with decreasing HCV infection, while chronic hepatitis D constituted the majority of increasing cases. A minority received therapy, with most patients showing an intermediate to high risk of liver cancer. More efforts are needed to improve linkage to care and access to therapy, especially in middle‐aged individuals at higher risk of liver disease progression.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015–2023
Date Crossref
06/01/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Liver Disease Diagnosis and TreatmentHepatitis C virus researchLiver Diseases and Immunity

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.